About NovellusDx
NovellusDx is a company based in Jerusalem (Israel) founded in 2011. NovellusDx has raised $85.5 million across 4 funding rounds from investors including Novartis, Orbimed and GSK. NovellusDx operates in a competitive market with competitors including GRAIL, Color, Omniome, Earli and NeoGenomics, among others.
- Headquarter Jerusalem, Israel
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$85.5 M (USD)
in 4 rounds
-
Latest Funding Round
$57 M (USD), Series C
Sep 21, 2020
-
Investors
Novartis
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NovellusDx
NovellusDx has successfully raised a total of $85.5M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $57 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NovellusDx
NovellusDx has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Orbimed and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pontifax Venture Capital is focused on life sciences investments.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked |
Investor details for NovellusDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NovellusDx
Investment portfolio details for NovellusDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NovellusDx
Detailed financials for NovellusDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novellusdx Comparisons
Peer comparison for NovellusDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NovellusDx
NovellusDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Omniome, Earli and NeoGenomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| Locked | Locked | Locked |
Cancer genetic diagnostic services are provided through specialized lab networks.
|
|
| Locked | Locked | Locked |
New genome engineering technology is provided for treating multiple diseases.
|
Detailed competitors of NovellusDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novellusdx
Complete news archive for NovellusDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovellusDx
NovellusDx was founded in 2011 and raised its 1st funding round 4 years after it was founded.
NovellusDx is headquartered in Jerusalem, Israel. It is registered at Jerusalem, Jerusalem District, Israel.
NovellusDx is a funded company, having raised a total of $85.5M across 4 funding rounds to date.
NovellusDx was founded in 2011 in Jerusalem, Israel, within the biotechnology sector focused on precision medicine. Technology is developed to track outcomes of DNA mutations, assess their functional and clinical impacts, and evaluate drug effects on specific tumors. Operations center on advancing diagnostic and therapeutic tools for oncology, with applications in personalized cancer treatment strategies.
NovellusDx's top competitors include GRAIL, Tessera Therapeutics and Phase Genomics.
NovellusDx has 10 investors. Key investors include Novartis, Orbimed, GSK, HBM Healthcare Investments, and Pontifax Venture Capital.